{"entity":{"id":"serd","kind":"term","name":"Selective oestrogen receptor degrader (SERD)","aka":["SERD","SERDs","oral SERDs","ER degrader","estrogen receptor degrader","SERM","selective oestrogen receptor modulator","CERAN","PROTAC ER degrader","oestrogen receptor degrader"],"tldr":"Drugs that do not just block the oestrogen receptor but mark it for destruction, so the cancer cell loses the receptor altogether. The new oral versions work even when the receptor has mutated (ESR1) to escape older hormone pills.","summary":"Fulvestrant (2002) is an injectable SERD limited by incomplete degradation; elacestrant (2023, EMERALD) was the first oral SERD, approved for ESR1-mutant metastatic disease, followed by camizestrant (SERENA-6, switching at ctDNA-detected ESR1 mutation), imlunestrant and vepdegestrant (a PROTAC). Oral SERDs are now in adjuvant trials (CAMBRIA, lidERA) and in combinations with CDK4/6 and PI3K/AKT inhibitors. Tamoxifen is the older selective modulator (SERM) that blocks the receptor in breast but stimulates it in bone and uterus.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Selective_estrogen_receptor_degrader","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Selective_estrogen_receptor_degrader"}],"tags":[],"related":["endocrine-resistance","aromatase-inhibitor","hormone-receptor-status"],"cancers":["breast-hr-positive"],"sections":["hormonal"],"technologies":["endocrine-therapy","protac-degrader"],"targets":["estrogen-receptor"],"drugs":["fulvestrant","elacestrant","tamoxifen"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["emerald","serena-6"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"category":"Treatment jargon"},"route":"/terms/serd/","neighbours":{"term":[{"id":"aromatase-inhibitor","kind":"term","name":"Aromatase inhibitor","route":"/terms/aromatase-inhibitor/"},{"id":"endocrine-resistance","kind":"term","name":"Endocrine resistance","route":"/terms/endocrine-resistance/"},{"id":"hormone-receptor-status","kind":"term","name":"Hormone receptor status (ER / PR)","route":"/terms/hormone-receptor-status/"}],"cancer":[{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"}],"section":[{"id":"hormonal","kind":"section","name":"Hormonal Therapy","route":"/fronts/hormonal/"}],"technology":[{"id":"endocrine-therapy","kind":"technology","name":"Endocrine therapy (SERMs, AIs, SERDs)","route":"/technologies/endocrine-therapy/"},{"id":"protac-degrader","kind":"technology","name":"PROTACs & molecular glues (targeted protein degradation)","route":"/technologies/protac-degrader/"}],"target":[{"id":"estrogen-receptor","kind":"target","name":"Estrogen receptor (ERα)","route":"/targets/estrogen-receptor/"}],"drug":[{"id":"elacestrant","kind":"drug","name":"Elacestrant","route":"/drugs/elacestrant/"},{"id":"fulvestrant","kind":"drug","name":"Fulvestrant","route":"/drugs/fulvestrant/"},{"id":"tamoxifen","kind":"drug","name":"Tamoxifen","route":"/drugs/tamoxifen/"}],"trial":[{"id":"emerald","kind":"trial","name":"EMERALD","route":"/trials/emerald/"},{"id":"serena-6","kind":"trial","name":"SERENA-6","route":"/trials/serena-6/"}],"biomarker":[{"id":"er-status","kind":"biomarker","name":"ER status (oestrogen receptor by IHC)","route":"/biomarkers/er-status/"},{"id":"esr1-mutation-ctdna","kind":"biomarker","name":"ESR1 mutation (ligand-binding domain, usually in ctDNA)","route":"/biomarkers/esr1-mutation-ctdna/"}]}}